Characteristic | Odds ratio | 95 % Confidence interval |
---|---|---|
Age (yr) | 1.01 | 0.99–1.03 |
Body mass index | 0.99 | 0.97 – 1.02 |
Gender (male vs. female) | 1.00 | 0.63–1.57 |
Ambulatory Status (ambulatory vs non-ambulatory) | 0.44 | 0.27 – 0.70 |
Alcohol use | 1.34 | 0.84–2.15 |
Surgery | 0.44 | 0.20–1.00 |
Coronary artery disease | 1.38 | 0.82–2.31 |
Chemotherapy | 0.26 | 0.09–0.75 |
Lung Disease | 1.16 | 0.60–2.24 |
Hypertension | 1.06 | 0.67–1.67 |
Immunosuppression | 0.93 | 0.58–1.48 |
Malnutrition | 1.67 | 0.94 – 2.95 |
Cancer | 0.59 | 0.35–1.01 |
Peripheral vascular disease | 1.80 | 0.83–3.90 |
Renal Failure | 0.65 | 0.36–1.19 |
Steroids | 0.81 | 0.50–1.32 |
Abdominal drain | 1.01 | 0.33–3.07 |
Non-insulin dependent diabetes | 1.59 | 0.81–3.13 |
Insulin-dependent diabetes | 0.93 | 0.53–1.63 |
Foley Catheter | 1.16 | 0.69–1.95 |
Hemodialysis | 1.39 | 0.57 – 3.35 |
Neutropenia | 1.17 | 0.32–4.28 |
Open wound | 1.09 | 0.63–1.90 |
Transplant | 1.00 | 0.58–1.71 |
Vascular catheter | 1.37 | 0.46 – 4.07 |
Vent support | 3.32 | 1.30–8.50 |
History of Candida | 2.07 | 1.11–3.84 |
History of MRSAӨ | 0.93 | 0.34–2.51 |
History of VREӨ | <0.001 | <0.001– >999.99 |
History of RGNӨ | 1.04 | 0.47–2.34 |
Days in hospital in 2 years. prior† (days) | 1.00 | 1.00–1.00 |
Days in ICU in 2 years. prior† (days) | 1.03 | 0.99–1.07 |
Aminoglycosidesa | 1.63 | 0.42– 6.26 |
Carbapenemsa | <0.001 | <0.001– >999.99 |
1st Gen Cephalosporinsa | 0.57 | 0.22–1.50 |
2nd Gen Cephalosporinsa | 0.47 | 0.06–3.76 |
3rd Gen Cephalosporinsa | 1.12 | 0.47–2.66 |
4th Gen Cephalosporinsa | 0.86 | 0.18–3.97 |
Glycopeptidesa | 1.22 | 0.51–2.91 |
Lincosamidesa | 1.95 | 0.78–4.88 |
Macrolidesa | 1.13 | 0.45–2.85 |
Nitrofuransa | 1.08 | 0.12–9.72 |
Penicillinsa | 1.02 | 0.38–2.79 |
Penicillin Combinationsa | 2.44 | 1.33–4.47 |
Fluoroquinolonesa | 3.25 | 1.98–5.32 |
Sulfonamidesa | 1.03 | 0.53–2.03 |
Tetracyclinesa | 8.75 | 0.79–97.51 |
Drugs against mycobacteriaa | 1.08 | 0.12–9.72 |
Other antibioticsb | 1.77 | 0.67–4.68 |